Companies: 10,795·Total market cap: $144.5T
Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

CHGCYOTCHealthcare● Active
$23.10
$-0.43(-1.83%)
Market Cap$76.0B
P/E Ratio—
52W High$34.84
52W Low$19.5
Overview

Chugai Pharmaceutical Co., Ltd. (CHGCY) Revenue

Annual & quarterly revenue history · segment & region breakdown

CHGCY · revenue · updated Jun 10, 2026

Core revenue metrics

Chugai Pharmaceutical Co., Ltd. trailing twelve-month (TTM) revenue is $1358B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$1358B
4-quarter sum · USD
YoY growth
+0.00%
vs FY —
Price / sales
0.06×
mktCap ÷ TTM rev
Revenue per day
$3721M
Est. TTM ÷ 365
Revenue / employee
$270220K
5026 employees
FY
—
FY
—
5Y CAGR
—
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Chugai Pharmaceutical Co., Ltd. SEC filings · GAAPUpdated: 2026-06-10

Revenue trend

– · Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
CHGCY revenue by year · CHGCY revenue history · CHGCY annual revenue data

Compare revenue vs peers

Drug Manufacturers - General

Compare CHGCY revenue against listed peers. Click any row to open that company's revenue tab.

GSK plc
GSK plc
GLAXF · $94.4B
→
Sartorius AG
Sartorius AG
SOAGY · $81.9B
→
Merck KGaA
Merck KGaA
MKGAF · $69.4B
→
Merck KGaA
Merck KGaA
MKKGY · $68.8B
→
Ipsen S.A.
Ipsen S.A.
IPSEY · $61.8B
→
HOYA Corporation
HOYA Corporation
HOCPY · $55.9B
→

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Chugai Pharmaceutical Co., Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Chugai Pharmaceutical Co., Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Chugai Pharmaceutical Co., Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.
Price historyFinancial statementsForecast

Frequently asked questions

CHGCY revenue · 4 questions

CHGCY's trailing twelve-month (TTM) revenue is $1358B. That is an increase of 0.00% year-over-year from — in FY.

CHGCY revenueCHGCY annual revenuewhat is CHGCY revenueCHGCY TTM revenue

▸ Source: FMP · Chugai Pharmaceutical Co., Ltd. SEC filings · GAAP · Chugai Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026